Acadian Asset Management
RVNC

Acadian Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Acadian Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,276
Closed -$37K – 2263
2024
Q3 		$37K Buy
+7,276
New +$36.2K ﹤0.01% 1887
2017
Q2 		– Sell
-35,338
Closed -$735K – 1620
2017
Q1 		$735K Buy
+35,338
New +$726K ﹤0.01% 814

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Acadian Asset Management's RVNC Position: Q4 2024 in Review

Acadian Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 7,276 shares — an estimated $37K sold.

Acadian Asset Management first reported a position in RVNC in Q1 2017 and held it in 2 quarters. The position peaked at $735K in Q1 2017. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Acadian Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 7,276 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $37K.
  • Acadian Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 2 quarters.
  • Acadian Asset Management's Revance Therapeutics, Inc. position peaked at $735K in Q1 2017.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.